"CNBC"

#12637316

12 August 2025

Stephen Miran is asked to be on the Federal Reserve Board of Governors. He has an interview with CNBC at the White House. He does not stop and talk to the press in Washington, DC, on August 12

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12637317

12 August 2025

Stephen Miran is asked to be on the Federal Reserve Board of Governors. He has an interview with CNBC at the White House. He does not stop and talk to the press in Washington, DC, on August 12

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12637319

12 August 2025

Stephen Miran is asked to be on the Federal Reserve Board of Governors. He has an interview with CNBC at the White House. He does not stop and talk to the press in Washington, DC, on August 12

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12637320

12 August 2025

Stephen Miran is asked to be on the Federal Reserve Board of Governors. He has an interview with CNBC at the White House. He does not stop and talk to the press in Washington, DC, on August 12

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12637322

12 August 2025

Stephen Miran is asked to be on the Federal Reserve Board of Governors. He has an interview with CNBC at the White House. He does not stop and talk to the press in Washington, DC, on August 12

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12625475

8 August 2025

A general view shows medicines on display at a pharmacy in Srinagar, Jammu and Kashmir, on August 8, 2025. President Donald Trump tells CNBC's ''Squawk Box'' on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he has threatened so far. Meanwhile, in an escalation of trade tensions between the United States and India, U.S. President Donald Trump, on August 6, 2025, signs an executive order imposing a 25 percent ad valorem tariff on all Indian imports into the United States. The ad valorem duty imposed in Executive Order 14257 applies in addition to the ad valorem duty imposed in section 2 of the order. This effectively means some categories of Indian exports may face a combined tariff burden of over 50 percent, depending on their classification.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12625476

8 August 2025

An employee checks medicine at a pharmacy in Srinagar, Jammu and Kashmir, on August 8, 2025. President Donald Trump tells CNBC's ''Squawk Box'' on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he threatens so far. Meanwhile, in an escalation of trade tensions between the United States and India, US President Donald Trump, on August 6, 2025, signs an executive order imposing a 25 percent ad valorem tariff on all Indian imports into the United States. The ad valorem duty imposed in Executive Order 14257 applies in addition to the ad valorem duty imposed in section 2 of the order. This effectively means some categories of Indian exports may face a combined tariff burden of over 50 percent, depending on their classification.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12625477

8 August 2025

An employee checks the stock of medicines at a pharmacy in Srinagar, Jammu and Kashmir, on August 8, 2025. President Donald Trump tells CNBC's ''Squawk Box'' on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he threatens so far. Meanwhile, in an escalation of trade tensions between the United States and India, US President Donald Trump, on August 6, 2025, signs an executive order imposing a 25 percent ad valorem tariff on all Indian imports into the United States. The ad valorem duty imposed in Executive Order 14257 applies in addition to the ad valorem duty imposed in section 2 of the order. This effectively means some categories of Indian exports may face a combined tariff burden of over 50 percent, depending on their classification.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12625478

8 August 2025

An employee arranges medicines at a pharmacy in Srinagar, Jammu and Kashmir, on August 8, 2025. President Donald Trump tells CNBC's ''Squawk Box'' on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he threatens so far. Meanwhile, in an escalation of trade tensions between the United States and India, US President Donald Trump, on August 6, 2025, signs an executive order imposing a 25 percent ad valorem tariff on all Indian imports into the United States. The ad valorem duty imposed in Executive Order 14257 applies in addition to the ad valorem duty imposed in section 2 of the order. This effectively means some categories of Indian exports may face a combined tariff burden of over 50 percent, depending on their classification.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12625479

8 August 2025

An employee arranges medicines at a pharmacy in Srinagar, Jammu and Kashmir, on August 8, 2025. President Donald Trump tells CNBC's ''Squawk Box'' on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he threatens so far. Meanwhile, in an escalation of trade tensions between the United States and India, US President Donald Trump, on August 6, 2025, signs an executive order imposing a 25 percent ad valorem tariff on all Indian imports into the United States. The ad valorem duty imposed in Executive Order 14257 applies in addition to the ad valorem duty imposed in section 2 of the order. This effectively means some categories of Indian exports may face a combined tariff burden of over 50 percent, depending on their classification.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#12625480

8 August 2025

A woman walks past a closed pharmacy in Srinagar, Jammu and Kashmir, on August 8, 2025. President Donald Trump tells CNBC's ''Squawk Box'' on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he threatens so far. Meanwhile, in an escalation of trade tensions between the United States and India, US President Donald Trump, on August 6, 2025, signs an executive order imposing a 25 percent ad valorem tariff on all Indian imports into the United States. The ad valorem duty imposed in Executive Order 14257 applies in addition to the ad valorem duty imposed in section 2 of the order. This effectively means some categories of Indian exports may face a combined tariff burden of over 50 percent, depending on their classification.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11977129

24 January 2025

LAS VEGAS, USA - JANUARY 8: Julie Sweet, Chair and CEO of Accenture, engages in a keynote conversation with Julia Boorstin, CNBC's Senior Media & Tech Correspondent, sharing her vision for the transformative role of AI and its far-reaching impacts on the future of business operations, at the 2025 CES 2025, in Las Vegas, Nevada, on January 8, 2025,

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11977130

24 January 2025

LAS VEGAS, USA - JANUARY 8: Julie Sweet, Chair and CEO of Accenture, engages in a keynote conversation with Julia Boorstin, CNBC's Senior Media & Tech Correspondent, sharing her vision for the transformative role of AI and its far-reaching impacts on the future of business operations, at the 2025 CES 2025, in Las Vegas, Nevada, on January 8, 2025,

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11977124

24 January 2025

LAS VEGAS, USA - JANUARY 8: Julie Sweet, Chair and CEO of Accenture, engages in a keynote conversation with Julia Boorstin, CNBC's Senior Media & Tech Correspondent, sharing her vision for the transformative role of AI and its far-reaching impacts on the future of business operations, at the 2025 CES 2025, in Las Vegas, Nevada, on January 8, 2025,

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11977125

24 January 2025

LAS VEGAS, USA - JANUARY 8: Julie Sweet, Chair and CEO of Accenture, engages in a keynote conversation with Julia Boorstin, CNBC's Senior Media & Tech Correspondent, sharing her vision for the transformative role of AI and its far-reaching impacts on the future of business operations, at the 2025 CES 2025, in Las Vegas, Nevada, on January 8, 2025,

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11977126

24 January 2025

LAS VEGAS, USA - JANUARY 8: Julie Sweet, Chair and CEO of Accenture, engages in a keynote conversation with Julia Boorstin, CNBC's Senior Media & Tech Correspondent, sharing her vision for the transformative role of AI and its far-reaching impacts on the future of business operations, at the 2025 CES 2025, in Las Vegas, Nevada, on January 8, 2025,

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.